

Abstract Disclosure Index

The following disclosure information has been provided for one or more authors of each abstract.

An asterisk (*) indicates no significant financial relationship to disclose.

‡ Abstract retracted because the first author on this abstract did not comply with ASCO's Conflict of Interest Policy and other abstract submission requirements.

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|-----------------|-----------------------------------|--|-----------------|---------------------|--|------------------|---------------------|
| 1 | | | | | | | |
| 2 | | | | | | | |
| 3 | | | | | | | |
| 4‡ | | | | | | | |
| 5 | | | | | | | |
| 6 | | | | | | | |
| 7 | | | | | | | |
| 8 | | | | | Taiho Pharma, USA | | |
| 9 | | | | | | | |
| 10 | | | | | | | |
| 11 | | | | | | | |
| 12 | | | | | | | |
| 13 | Novartis | Novartis | | Novartis | Novartis | | |
| 14 | | | | | | | |
| 15 | | | | | | | |
| 16 | Novartis | GlaxoSmithKline, MedImmune, Novartis, Pfizer, sanofi-aventis | | Novartis, PharmaMar | Novartis | | Novartis, PharmaMar |
| 17 | | | | | | | |
| 18 | | | | | | | |
| 19 | | | | | | | |
| 20 | | | | | | | |
| 21 | | | | | | | |
| 22 | | | | | | | |
| 23 | | | | | | | |
| 24 | | | | | | | |
| 25 | | | | | | | |
| 26 | | | | | | | |
| 27 | | | | | | | |
| 28 | | | | | | | |
| 29 | | | | | | | |
| 30 | | | | Merck, Roche | AstraZeneca Oncology, Bristol-Myers Squibb, OSI Oncology, sanofi-aventis | | |
| 31 | | | | | | | |
| 32 | | | | | | | |

ABSTRACT DISCLOSURE INDEX

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|-----------------|-----------------------------------|---|----------------------|---|--|--|--------------------|
| 33 | | | | | | | |
| 34 | | | | | | | |
| 35 | | | | | | | |
| 36 | | | | | | | |
| 37 | | | | | | | |
| 38 | | | | | | | |
| 39^ | | | | | | | |
| 41 | | | | | | | |
| 42 | | | | | | | |
| 43 | | Amgen, Ariad, Novartis, Pfizer, Roche, sanofi-aventis | | Amgen, ImClone, Novartis, Pfizer, Roche, sanofi-aventis | Amgen, MerckSerono, Novartis, Pfizer, sanofi-aventis | Amgen, Fulcrum, MerckSerono, Novartis, Pfizer, Roche, sanofi-aventis | |
| 44 | | | | | | | |
| 45 | | | | | | | |
| 46 | | | | | | | |
| 47 | | | | | sanofi-aventis | | |
| 48 | Bristol-Myers Squibb | | Bristol-Myers Squibb | Bristol-Myers Squibb | | | |
| 49 | | | | | | | |
| 50 | | | | | | | |
| 51 | | | | | | | |
| 52 | | | | | | | |
| 53 | | | | | | | |
| 54 | | | | | | | |
| 55 | | | | | Roche | | |
| 56 | | | | | | | |
| 57 | Roche | Roche | | Roche | Roche | | |
| 58 | | Bristol-Myers Squibb, ImClone Systems Incorporated, Roche, sanofi-aventis | | Bristol-Myers Squibb, sanofi-aventis | | | |
| 59 | | | | | | | |
| 60 | | | | | | | |
| 61 | | | | | | | |
| 62 | | | | | | | |
| 63 | | | | | | | |
| 64 | | | | | | | |
| 65 | | | | | | | |
| 66 | | | | | | | |
| 67 | | | | | | | |

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|-----------------|-----------------------------------|-----------------------------|-----------------|----------------------------|---|------------------|--------------------|
| 68 | | | | | | | |
| 69 | | | | | | | |
| 70 | | | | | | | |
| 71 | | | | | | | |
| 72 | | | | | | | |
| 73 | | | | | | | |
| 74 | | | | | | | |
| 75 | | | | | | | |
| 76 | | | | | | | |
| 77 | Novartis | | | | | | |
| 78 | | | | | | | |
| 79 | | Merck, Nektar | | Genentech, sanofi-aventis | Bristol-Myers Squibb, Genentech, sanofi-aventis | | |
| 80 | | Attenuon LLC | | | | | |
| 81 | | | | | | | |
| 82 | | | | | | | |
| 83 | | | | | | | |
| 84 | | Pfizer, sanofi-aventis | | | Genentech, Roche, sanofi-aventis | | |
| 86 | Novartis | | | | Novartis | | |
| 87 | | | | | | | |
| 88 | | | | | | | |
| 89 | | | | | | | |
| 90 | | | | | | | |
| 91 | | | | | | | |
| 92 | | | | | | | |
| 93 | Novartis | Novartis | Novartis | | | | |
| 94 | | | | AstraZeneca, Pfizer, Roche | | | |
| 95 | | | | | | | |
| 96 | | | | Tomotherapy | | | |
| 97 | | | | | | | |
| 98 | | | | | | | |
| 99 | | | | Roche, sanofi-aventis | Roche, sanofi-aventis | | |
| 100 | | | | | | | |
| 101 | | | | | | | |
| 102 | | | | Taiho | | | |
| 103 | | | | | | | |
| 104 | | | | | | | |
| 105 | | | | | | | |

ABSTRACT DISCLOSURE INDEX

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|-----------------|--|---|--------------------|----------------------------|------------------|------------------|--------------------|
| 106 | | | | | | | |
| 107 | | | | | | | |
| 108 | | | | | | | |
| 109 | | | | Pfizer | | | |
| 110 | | | | | | | |
| 111 | American College of Radiology | | | | | | |
| 112 | | | | | | | |
| 113 | Immunomedics, Inc, | | Immunomedics, Inc. | | | | |
| 114 | | | | | | | |
| 115 | | | | | | | |
| 116 | | | | | | | |
| 117 | Roche | Roche | | | Roche | | |
| 118 | | | | | | | |
| 119 | Bayer, Bayer Schering Pharma, VP Global Clinical Development | Bayer, Bayer Schering Pharma, MerckSerono, Pfizer | Bayer | Bayer, MerckSerono, Pfizer | Bayer | | |
| 120^ | MediGene AG | | | MediGene AG | | | |
| 121 | | | | Novartis | Novartis | | |
| 122 | Novartis | Novartis | Novartis | Novartis | Novartis | | |
| 123 | | | | | | | |
| 124 | | | | | | | |
| 125 | | | | | | | |
| 126 | | | | | | | |
| 127 | | | | | | | |
| 128 | | | | | | | |
| 129 | | | | | | | |
| 130 | | | | | | | |
| 131 | | | | | | | |
| 132 | | | | | | | |
| 133 | | | | | | | |
| 134 | | Bayer | | | | | Bayer |
| 135 | | | | | | | |
| 136 | | | | | | | |
| 137 | | | | | | | |
| 138 | | | | | | | |
| 139 | | | | | | | |
| 140 | | | | | | | |
| 141 | | | | | | | |
| 142 | | | | | | | |

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|-----------------|--|-----------------------------|---------------------|---------------------|---|------------------|--------------------|
| 143 | | | | | | | |
| 144 | | | | | | | |
| 145 | | | | | | | |
| 146 | | | | | | | |
| 147 | | | | | | | |
| 148 | | | | | | | |
| 149 | | | | | | | |
| 150 | | | | | | | |
| 151 | | | | | | | |
| 152 | | | | | Medarex | | |
| 153 | Medarex | | | | | | |
| 154 | | | | | | | |
| 155 | | | | | | | |
| 156 | | | | | | | |
| 157 | | | | | | | |
| 158 | | | | | | | |
| 159 | | | | | | | |
| 160 | | | | Roche | | | Roche |
| 161 | | | | | | | |
| 162 | | | | | Novartis | | |
| 163 | IBC Pharmaceuticals, Inc, Immunomedics, Inc. | Immunomedics, Inc. | | | | | |
| 164 | Bipar Sciences Inc. | Bipar Sciences Inc. | Bipar Sciences Inc. | Bipar Sciences Inc. | | | |
| 165 | | | | | | | |
| 166 | | | | | | | |
| 167 | | | | Eli Lilly | National Institute of Biomedical Innovation | | |
| 168 | Immunomedics, Inc, | | Immunomedics, Inc. | | | | |
| 169 | | | | | Bristol-Myers Squibb | | |
| 170 | | | | | | | |
| 171 | | | | | | | |
| 172 | Phytoceutica | | PhytoCeutica | | | | |
| 173 | | | | | | | |
| 174 | | | | | | | |
| 175 | | | | | | | |
| 176 | | | | | | | |

ABSTRACT DISCLOSURE INDEX

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|------------------------|--|------------------------------------|------------------------|--|--|-------------------------|---------------------------|
| 177 | | Genentech, ImClone | | | | | |
| 178 | | | | | | | |
| 179 | | | | | | | |
| 180 | | | | | | | |
| 181 | | | | | | | |
| 182 | | | | | | | |
| 183 | ImClone Systems Incorporated | Bristol-Myers Squibb, ImClone | | Abraxis Biosciences, Genentech, sanofi-aventis | Bristol-Myers Squibb, Eli Lilly, Genentech, ImClone Systems Incorporated | | |
| 184 | | | | | | | |
| 185 | | | | | | | |
| 186 | | | | | | | |
| 187 | | | | | American Cancer Society | | |
| 188 | AstraZeneca Oncology | AstraZeneca Oncology | | | | | |
| 189 | Eli Lilly and Company | | Eli Lilly and Company | | | | |
| 190 | | | | | | | |
| 191 | | | | | | | |
| 192 | Amgen | Amgen | Amgen | | Amgen, Eli Lilly | | |
| 193 | Archer Biosciences, Inc. | | | | | | |
| 194 | | | | | Roche, sanofi-aventis | | |
| 195 | Taiho | | | | | | |
| 196 | | | | | sanofi-aventis | | |
| 197 | | | | | Bristol-Myers Squibb | | |
| 198 | | Bayer | | Bayer | | | |
| 199 | | | | | | | |
| 200 | Bristol-Myers Squibb | | | | | | |
| 201 | | | | | | | |
| 202 | | | | | | | |
| 203 | | | | | | | |
| 204 | | AstraZeneca | | AstraZeneca | AstraZeneca | | |
| 205 | | | | | | | |
| 206 | Celgene | Celgene | Celgene | | Celgene | | |
| 207 | | | | | | | |
| 208 | | | | | | | |
| 209 | | | | | | | |

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|-----------------|-----------------------------------|-----------------------------|-----------------|-----------|-------------------------|------------------|--------------------|
| 210 | | | | | | | |
| 211 | | | | | | | |
| 212 | | | | | | | |
| 213 | | | | | | | |
| 214 | | | | | | | |
| 215 | | | | | | | |
| 216 | | | | | | | |
| 217 | | | | | | | |
| 218 | | | | | | | |
| 219 | | | | | | | |
| 220 | | | | | | | |
| 221 | | | | | | | |
| 222 | | | | | | | |
| 223 | | | | | | | |
| 224 | | | | | | | |
| 225 | | | | | | | |
| 226 | | | | | | | |
| 227 | | | | | | | |
| 228 | | | | | Genentech | | |
| 229 | | | | | | | |
| 230 | | | | | | | |
| 231 | | | | | | | |
| 232 | | | | | | | |
| 233 | | | | | Angiodynamics | Biocompatibles | |
| 234 | | | | | | | |
| 235 | | | | | | | |
| 236 | | | | | | | |
| 237 | | | | | | | |
| 238 | | | | | | | |
| 239 | | | | | Elekta Oncology Systems | | |
| 240 | | | | | | | |
| 241 | | | | | | | |
| 242 | AB Science | | AB Science | | AB Science | | |
| 243 | | | | | | | |
| 244 | | | | | | | |
| 245 | | | | | | | |
| 246 | | | | | Novartis | | |
| 247 | MolMed | | | | | | |
| 248 | | | | | | | |

ABSTRACT DISCLOSURE INDEX

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|------------------------|--|------------------------------------|------------------------------------|-----------------------|------------------------------------|-------------------------|---------------------------|
| 249 | Epeius Biotechnologies Corporation | | Epeius Biotechnologies Corporation | | Epeius Biotechnologies Corporation | | |
| 250 | | | | | | | |
| 251 | | | | | | | |
| 252 | | | | | | | |
| 253 | | | | | | | |
| 254 | | | | | | | |
| 255 | | | | | | | |
| 256 | | | | | | | |
| 257 | | Tomotherapy | Tomotherapy | | | | |
| 258 | | | | | | | |
| 259 | | | | | | | |
| 260 | | | | Sirtex Medical | | | |
| 261 | | | | | | | |
| 262 | | | | | | | |
| 263 | | | | | | | |
| 264 | | | | Genentech BioOncology | Genentech BioOncology | | |
| 265 | | | | | | | |
| 266 | | | | | | | |
| 267 | | | | | | | |
| 268 | | | | | | | |
| 269 | | | | | | | |
| 270 | | | | | | | |
| 271 | Bayer | Bayer | | Bayer | Bayer | | |
| 272 | | | | | Pfizer Oncology | | |
| 273 | | | | | | | |
| 274 | | | | Angiodynamics | Angiodynamics | | |
| 275 | | | | | | | |
| 276 | | Bristol-Myers Squibb | | Bristol-Myers Squibb | Bristol-Myers Squibb | | |
| 277 | | | | | | | |
| 278 | | | | | | | |
| 279 | | | | | | | |
| 280 | | | | | | | |
| 281 | | | | | Eli Lilly | | |
| 282 | | | | | | | |
| 283 | | | | | | | |
| 284 | | | | | | | |
| 285 | | | | | | | |
| 286 | | | | | | | |
| 287 | | | | | | | |

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|------------------------|--|------------------------------------|------------------------|---|--|-------------------------|---------------------------|
| 288 | | Pfizer Oncology | | Pfizer Oncology | Pfizer Oncology | | |
| 289 | | | | | Merck Serono | | |
| 290^ | | sanofi-aventis | | sanofi-aventis | | | |
| 291 | Amgen | Amgen, Genentech, ImClone, Onyx | Amgen | Amgen, Bayer, Bristol-Myers Squibb, ImClone, Onyx | Amgen, Hana Biosciences | | |
| 292 | | | | | | | |
| 293 | | | | | | | |
| 294 | | | | | | | |
| 295 | | Genentech, sanofi-aventis | | Genentech, sanofi-aventis | Cancer Fighters of Houston, sanofi-aventis | | |
| 296 | | | | Merck KGaA, Pfizer, sanofi-aventis | Merck KGaA, Pfizer, sanofi-aventis | | |
| 297 | | | | | | | |
| 298 | | ImClone Systems Incorporated | | | ImClone Systems Incorporated | | |
| 299 | | | | | | | |
| 300 | | | | | | | |
| 301 | | | | | | | |
| 302 | | | | | | | |
| 303 | | | | | | | |
| 304 | | | | | | | |
| 305 | | | | | | | |
| 306 | | | | | | | |
| 307 | | | | | | | |
| 308 | | | | | | | |
| 309 | | | | | | | |
| 310 | | | | | | | |
| 311 | | | | | | | |
| 312 | | | | | | | |
| 313 | Pathwork Diagnostics | | Pathwork Diagnostics | | Pathwork Diagnostics | | |
| 314 | | | | | | | |
| 315 | | | | | | | |
| 316 | Milagen, Inc. | | Milagen, Inc. | | | | |
| 317 | | | | | | | |
| 318 | Rosetta Genomics | Rosetta Genomics | Rosetta Genomics | | | | |
| 319 | | | | | | | |
| 320 | | | | | | | |
| 321 | Amgen | | Amgen | | | | |

ABSTRACT DISCLOSURE INDEX

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|------------------------|--|---|------------------------|--|--------------------------------------|-------------------------|---------------------------|
| 322 | | | | | | | |
| 323 | | | | | | | |
| 324 | | | | | | | |
| 325 | | | | | | | |
| 326 | | | | | | | |
| 327 | | | | | | | |
| 328 | | | | | | | |
| 329 | | | | | | | |
| 330 | | | | | | | |
| 331 | | | | | | | |
| 332 | | | | | | | |
| 333 | TopoTarget A/S | TopoTarget A/S | TopoTarget A/S | | | | |
| 334 | | | | | | | |
| 335 | Immunomedics, Inc. | Immunomedics, Inc. | | | | | |
| 336 | | | | | sanofi-aventis | | |
| 337 | | | | | | | |
| 338 | MediGene AG | MediGene Inc | MediGene AG | | MediGene Inc | | |
| 339 | | | | | | | |
| 340 | | Chiron, Genentech, Response Genetics, Inc | | Lilly, Novartis, Pfizer, Roche, sanofi-aventis | | | |
| 341 | Bristol-Myers Squibb | Bristol-Myers Squibb, ImClone Systems Incorporated, Roche, sanofi-aventis | Bristol-Myers Squibb | Genentech BioOncology | Bristol-Myers Squibb, sanofi-aventis | | |
| 342 | Boehringer Ingelheim Pharma GmbH, Boehringer Ingelheim RCV | | | Boehringer Ingelheim RCV, Austria | | | |
| 343 | | | | | | | |
| 344 | | | | | | | |
| 345 | | | | | | | |
| 346 | | | | | | | |
| 347 | | | | | | | |
| 348 | | | | | | | |
| 349 | | | | | | | |
| 350 | | | | | | | |
| 351 | | | | | | | |
| 352 | | | | | | | |
| 353 | | | | | | | |
| 354 | | | | | | | |

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|-----------------|------------------------------------|-----------------------------|-----------------|---|---|------------------|-----------------------|
| 355 | | | | | | | |
| 356 | | | | | | | |
| 357 | | | | | | | |
| 358 | | | | | | | |
| 359 | | | | | | | |
| 360 | | Genentech BioOncology | | Genentech BioOncology (2006) | Amgen, Genentech BioOncology, GlaxoSmithKline, Novartis, Pfizer Oncology | | |
| 361 | | | | | | | |
| 362 | Hoffman-La Roche, Plexxikon, Roche | | Plexxikon | | | | |
| 363 | | | | | Lilly Oncology | | |
| 364 | | | | | | | |
| 365 | | | | | | | |
| 366 | | | | | | | |
| 367 | | | | | | | |
| 368 | | | | | | | |
| 369 | | | | | | | |
| 370 | | | | | | | |
| 371 | | | | | | | |
| 372 | | | | | | | |
| 373 | | | | | | | |
| 374 | | | | | | | |
| 375 | Bristol-Myers Squibb | | | | | | |
| 376 | | | | | | | |
| 377 | | | | | | | |
| 378 | | | | | | | |
| 379 | | | | Hoffmann - La Roche Ltd. Representative Office Skopje | Hoffmann - La Roche Ltd. Representative Office Skopje, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy | | |
| 380 | | | | | | | |
| 381^ | | Merck, Pfizer | | Merck, Pfizer | | | Merck, sanofi-aventis |

ABSTRACT DISCLOSURE INDEX

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|-----------------|-----------------------------------|--|---|-----------------------|-----------------------|------------------|---|
| 382 | Roche | Amgen, Baxter, Pfizer, Roche, sanofi-aventis, Teva-Medical | Roche (Member of Roche Connect and owing Roche Genusschein) | Roche, sanofi-aventis | Roche, sanofi-aventis | | Roche (for lectures as invited speaker), sanofi-aventis (for lectures as invited speaker) |
| 383 | | | | | | | |
| 384 | | | | | | | |
| 385 | | | | | NCIC | | |
| 386 | Amgen | Abraxis, Adnexus, Amgen, Anandys, Ariad Pharmaceuticals Inc, Astellas, AstraZeneca, Biogen Idec Inc, Centocor, Chemokine, Curis, Cytokinetics, Dendreon Corp, Ely Lilly, Enzon, Exelixis, Fibrogen, Five Prime Therapeutics Inc, Genentech, Genetics Squared, Genta, Geron, HUYA Bioscience International, Immunogen, Johnson and Johnson, Merck, MGI Pharma Inc, Micromet, NCI Drug Development Group, Nectar, Nerius, Nervianoms, Onyx Pharmaceuticals, Paramount Biosciences, LLC, Pfizer, Sankyo, sanofi-aventis, Santaris, Schering-Plough, Spectrum, Supergen, Symphogen, Takeda | Amgen | | Amgen | | |
| 387 | | | | | | | |

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|-----------------|-----------------------------------|---|--|---|---|------------------|--------------------|
| 388 | Amgen | | Amgen | Various | | | Various |
| 389 | | | | | | | |
| 390 | Amgen | Alnylam, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Delcath, Genentech, ImClone, Merck, Pfizer, Roche, sanofi-aventis, YM Bioscience | Amgen | | Amgen, Bayer, Bristol-Myers Squibb, Genentech, ImClone, Merck, Pfizer, Roche, Taiho | | |
| 391 | | | | | | | |
| 392 | | | | | | | |
| 393 | | | | | sanofi-aventis | | |
| 394 | Amgen | Amgen, Genentech, ImClone, Onyx | Amgen | Amgen, Bayer, Bristol-Myers Squibb, ImClone, Onyx | Amgen, Hana Biosciences | | |
| 395 | Adjuvant! Inc | Amgen Inc, Bayer Pharmaceuticals Corpora, Bristol-Myers Squibb Company, Celgene Corporation, Delcath Systems Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems Incorporated, Pfizer Inc, Roche Laboratories Inc, Saladax Biomedical, sanofi-aventis, Zealand Pharma A/S | Adjuvant! Inc, Bristol-Myers Squibb Company, Pfizer Inc, Saladax Biomedical, Wyeth | AstraZeneca Pharmaceuticals LP, Biogen Idec | Amgen Inc, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Genentech BioOncology, ImClone Systems Incorporated, Pfizer Inc, Roche Laboratories Inc, sanofi-aventis | | |
| 396 | | | | | | | |
| 397 | | | | | | | |
| 398 | | | | | | | |
| 399 | | | | | | | |
| 400 | | | | | | | |
| 401 | | | | | | | |
| 402 | | | | | | | |
| 403 | | | | | | | |
| 404 | | | | | | | |

ABSTRACT DISCLOSURE INDEX

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|-----------------|-----------------------------------|--|-----------------|--|-------------------------------|--|--------------------|
| 405 | | | | | | | |
| 406 | | Nordion | | | Nordion | | |
| 407 | | | | | | | |
| 408 | | | | | | | |
| 409 | | | | | | | |
| 410 | sanofi-aventis | | | | | | |
| 411 | | | | | | | |
| 412 | | | | | | | |
| 413 | Roche | Roche | | Roche | Roche | | |
| 414 | | | | | | | |
| 415 | | | | | | | |
| 416 | | | | | | | |
| 417 | | | | | | | |
| 418 | Roche | Roche | | Roche | Roche | | |
| 419 | Sirtex Medical | | Sirtex Medical | Sirtex Medical | | | |
| 420 | Roche | | | | | | |
| 421 | | | | | | | |
| 422 | Roche | Roche | | Roche | Roche | | |
| 423 | | | | | | | |
| 424 | Roche | | | | | | |
| 425 | | | | | | | |
| 426 | | | | | | | |
| 428 | | Amgen Austria | | Various | Amgen | | Various |
| 429 | | | | | | | |
| 430 | | | | | | | |
| 431 | | | | | | | |
| 432 | | | | | | | |
| 433 | | | | | | | |
| 434 | | | | | | | |
| 435 | | | | | | | |
| 436 | | | | | | | |
| 437 | Takeda Bio Development, Ltd. | | | | | | |
| 438 | | | | | | | |
| 439 | | | | | | | |
| 440 | | | | | | | |
| 441 | | | | | | | |
| 442 | | | | | | | |
| 443 | Merck | Merck, Pfizer Oncology, sanofi-aventis | | Amgen, Merck, Pfizer Oncology, Roche, sanofi-aventis | Amgen, Merck, Pfizer Oncology | Amgen, Merck, Pfizer Oncology, Roche, sanofi-aventis | |

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|------------------------|--|------------------------------------|-------------------------|--|--------------------------------|-------------------------|---------------------------|
| 444 | Poniard Pharmaceuticals | | Poniard Pharmaceuticals | | | | |
| 445 | Amgen | | Amgen | Amgen, Bristol-Myers Squibb, Centocor, Inc | | | |
| 446 | Novartis | Novartis | | Novartis, Roche, sanofi-aventis | Novartis | | |
| 447 | | Roche, sanofi-aventis | | Roche, sanofi-aventis | Roche, sanofi-aventis | | Roche, sanofi-aventis |
| 448 | | | | | | | |
| 449 | | | | | | | |
| 450 | | Merck, Pfizer | | Pfizer | | | |
| 451 | | | | | | | |
| 452 | | | | | | | |
| 453 | | | | | | | |
| 454 | MolMed | | | | | | |
| 455 | | | | | | | |
| 456 | | | | | | | |
| 457 | | | | | | | |
| 458 | | | | | | | |
| 459 | | | | | | | |
| 460 | Roche | Roche | | Roche | | | |
| 461 | | | | | | | |
| 462 | | | | Genentech | Genentech, Novartis | | |
| 463 | | | | | | | |
| 464 | | | | | | | |
| 465 | | | | | | | |
| 466 | | | | | | | |
| 467 | | | | | | | |
| 468 | | | | | | | |
| 469 | | | | | | | |
| 470 | | | | | | | |
| 471 | | | | | | | |
| 472 | | | | | | | |
| 473 | | | | Sirtex Medical, Wilmington, MA | Sirtex Medical, Wilmington, MA | | |
| 474 | | | | | | | |
| 475 | | | | | | | |
| 476 | | | | | | | |
| 477 | | sanofi-aventis | | sanofi-aventis | sanofi-aventis | | |
| 478 | | | | | | | |
| 479 | | | | | | | |
| 480 | | | | | | | |

ABSTRACT DISCLOSURE INDEX

| Abstract Number | Employment or Leadership Position | Consultant or Advisory Role | Stock Ownership | Honoraria | Research Funding | Expert Testimony | Other Remuneration |
|-----------------|-----------------------------------|--------------------------------------|-----------------|--------------------------------------|--------------------------------|------------------|--------------------|
| 481 | | | | | | | |
| 482 | | | | | | | |
| 483 | | | | Amgen, Genentech, ImClone, Pfizer | Medimmune, sanofi-aventis | | |
| 484 | | | | | | | |
| 485 | | | | | Chugai Pharmaceutical co., LTD | | |
| 486 | | | | | | | |
| 487 | | | | | | | |
| 488 | | | | | | | |
| 489 | | | | | | | |
| 490 | | Bristol-Myers Squibb, sanofi-aventis | | Bristol-Myers Squibb, sanofi-aventis | | | |
| 491 | | | | | | | |
| 492 | | | | | | | |
| 493 | | | | | | | |
| 494 | | | | | | | |
| 495 | | | | | | | |
| 496 | | | | | | | |
| 497 | | ImClone, sanofi-aventis | | | | | |
| 498 | | | | | | | |
| 499 | | | | | | | |
| 500 | | | | | | | |
| 501 | | | | | | | |
| 502 | | | | | | | |